Advertisement
BMY vs XLV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Buy and XLV is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green while.
- BMY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 5 TA indicator(s) are bullish.
- BMY’s TA Score: 5 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.24% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +6.56%, and the average quarterly price growth was +4.69%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
BMY | ||
|---|---|---|
OUTLOOK RATING 1..100 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 91 | |
SMR RATING 1..100 | 25 | |
PRICE GROWTH RATING 1..100 | 50 | |
P/E GROWTH RATING 1..100 | 68 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BMY | XLV | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 52% | 3 days ago 81% |
| Stochastic ODDS (%) | 3 days ago 55% | 3 days ago 78% |
| Momentum ODDS (%) | 3 days ago 56% | 3 days ago 77% |
| MACD ODDS (%) | 3 days ago 46% | 3 days ago 83% |
| TrendWeek ODDS (%) | 3 days ago 56% | 3 days ago 81% |
| TrendMonth ODDS (%) | 3 days ago 55% | 3 days ago 83% |
| Advances ODDS (%) | 3 days ago 54% | 10 days ago 81% |
| Declines ODDS (%) | 13 days ago 54% | 13 days ago 84% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 87% |
| Aroon ODDS (%) | 3 days ago 54% | 3 days ago 83% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BRZU | 91.06 | 1.56 | +1.74% |
| Direxion Daily MSCI Brazil Bull 2X ETF | |||
| SLYV | 108.19 | 1.17 | +1.09% |
| State Street® SPDR® S&P 600™ Sm CpValETF | |||
| NPFD | 18.73 | 0.07 | +0.38% |
| Nuveen Variable Rate Preferred & Income Fund | |||
| WCPB | 25.33 | -0.02 | -0.06% |
| Weitz Core Plus Bond ETF | |||
| CATF | 50.23 | -0.04 | -0.07% |
| American Century California Muni Bd ETF | |||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +0.40% | ||
| PFE - BMY | 59% Loosely correlated | +0.15% | ||
| AMGN - BMY | 57% Loosely correlated | +0.32% | ||
| NVS - BMY | 55% Loosely correlated | -0.55% | ||
| GSK - BMY | 53% Loosely correlated | +0.34% | ||
| ABBV - BMY | 52% Loosely correlated | +1.32% | ||
More | ||||
XLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, XLV has been closely correlated with MRK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then MRK could also see price increases.